Cardiovascular events in systemic lupus erythematosus and rheumatoid arthritis: Emerging concepts, early diagnosis and management

Journal of Association of Physicians of India

Volumn 55, Issue JAN., 2007, Pages 32-40

  Chogle, A R ^a   Chakravarty, Anamika ^b  

^a I/C Rheumatology Clinic   (India)

^b Sir Hurkisondas Nurrotumdas Hospital & Research Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; EARLY DIAGNOSIS; HUMAN; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; EARLY DIAGNOSIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 34247501229     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Doria A, Sarzi-Puttini P. Heart, Rheumatism and autoimmunity: an old intriguing link. Lupus 2005;14:643-5.
2. Manzi S, Wasko NCM. Inflammation mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000;59:321-5.
3. Manzi S, Meilahn EN, Rairie JE, et al. Age specific incidence of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidem 1997;145:408-15.
4. Bhatt SP, Handa R, Gulti GS, et al. Atherosclerosis in Asian Indians with systemic lupus erythematosus. Scand J Rheumatol 2006;35:128-32.
5. Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiac involvement in systemic lupus erythematosus. Lupus 2005;14:683-6.
6. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail fully to account for accelerated atherosclerosis in systemic lupus erythematosus. Arthitis Rheum 2001;44:2331-7.
7. Hahn BH. Systemic Lupus Erythematosus and accelerated atherosclerosis. N Engl J Med 2003;349:2379-80.
8. Belmont HM, Abramson SB. Mechanisms of acute inflammation and vascular injury in systemic lupus erythematosus. In : Wallace DJ and Hahn BH eds Dubo's lupus erythematosus sixth edition. Lippincot Williams and Wilkins 2002:261-80.
9. Van Leuven SI, Kastelin JJP, D'Cruz DP et al. Atherogenesis in rheumatology. Lupus 2006;15:117-21.
10. Borba EF, Bonfa E, Vingare CCG et al. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000;43:1033-40.
11. Ettinger WH, Goldberg AP, Applebaum-Boweden D, et al. Dysliproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987;83:503-8.
12. McMahoh M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis. Arthritis Rheum 2006;54:2541-9.
13. Vaarala O, Alfthan G, Jauhiainen M, et al. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-5.
14. Shoenfeld Y, Wu R, Dearing LD, et al. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004;110:2552-8.
15. Petri M, Roubenoff R, Dallal GE et al. Plasma homocysteine as a risk factor for atherosclerotic events in systemic lupus erythematosus. Lancet 1996;348:1120-24.
16. Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat. The Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2003;52:2490-6.
17. Bonora E, Turgher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
18. Magadmi ME, Ahmad X, Tuskie W et al. Hypeinsulinemia, Insulin resistance and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumol 2006;33:50-6.
19. Aralos I, Chung CP, Oeser A et al. Decreased insulin sensitivity in systemic lupus erythematosus is associated with inflammation and cardiovascular risk (Abstract). Arthritis Rheum 2006;54:S271.
20. Adhiyaman V, Asghar M, Oke et al. Nephrotoxicity in the elderly due ot co-prescription of angiotensin converting enzyme inhibitors and non-steroidal anti-inflammatory drugs. J R Soc Med 2001;94:512-14.
21. Wallace DJ, Metzger AL, Stecher VJ et al. Cholesterol lowering effect of hydroxychloroquine in patients with rheumatic disease : reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322-6.
22. Nabel EG. Coronary heart disease in women - an ounce of prevention. N Engl J Med 2000;343:572-74.
23. Greenland P, Abram J, Aurigemma CP et al. Prevention conference V. Beyond secondary prevention : Identifying the high-risk patients for primary prevention : noninvasive tests of atherosclerotic burden : Working Group III. Circulation 2000;101:E:16-22.
24. Bruce IN, Burns RJ, Gladman DD, Urowitz MB. Single photon emission computed tomography (SPECT) in women with SLE. I : Prevalence and distribution of abnormalities. J Rheumatol 2000;27:2372-7.
25. Budoff MJ, Diamond GA, Raggi P, et al. Continuous probabilistic prediction of angiographically significant coronary artery disease using electron-beam tomography. Circulation 2002;105:1791-6.
26. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-415.
27. Ward MM. Recent improvements in survival in patients with rheumatoid arthritis : better outcomes or different study designs? Arthritis Rheum 2001;44:1467-9.
28. Myllykangas-Luosujarvi R, Aho K, Kautianene H, Isomaki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 1995;22:1065-7.
29. Maradit-Kremers H, Crowson CS, Nieola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. Arthritis Rheum 2005;52:402-11.
30. Grover S, Sinha RP, Singh U, et al. Subclinical atherosclerosis in rheumatoid arthritis in India. J Rheumatol 2006;33:244-7.
31. Dessein PH, Joffe BI. Editorial : When Is a Patient with Rheumatoid Arthritis at Risk for Cardiovascular Disease? The Journal of Rheumatology 2006;33:201-3.
32. McMahon M, Grossman J, Fitzgerald J, et al. Pro-inflammatory HDL as a biomarker for atherosclerosis in SLE and RA. Arthritis Rheum 2005;52:S697-S698.
33. Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005;32:435-42.
34. Pasceri V, yeh ET. A tale of two diseases : atherosclerosis and rheumatoid arthritis. Circulation 1999;100:2124-6.
35. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes : principles of pathogenesis and therapy. Lancet 2005;365:1333-46.
36. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in Rheumatoid Arthritis. Arthritis Rheum 2006;54:2765-75.
37. Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000;101:2883-8.
38. Pawlik A, Ostanek L, Brzosko I, et al. The expansion of CD4+ CD28- T cells in patients with rheumatoid arthritis. Arthritis Res Ther 2003;5:R210-13.
39. Gerli R, Schillaci G, Giordano A, et al. CD4+ CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004;109:2744-8.
40. McEntegart A, Capell HA, Creran D et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 2001;40:640-4.
41. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort : effects on lipids, glucose and thrombosis. Lupus 1996;5:S16-22.
42. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
43. Morgan SL, Baggott JE, Lee JY, et al. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long term, low dose methotrexate therapy for rheumatoid arthritis : implications for cardiovascular disease prevention. J Rheumatol 1998;25:441-6.
44. Roubenoff R, Dellaripa P, Nadeau MR, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997;40:718-22.
45. Joshi SR. Demystifying relevance of homocysteine hypothesis in Native Asian Indian population. J Assoc Physicians Ind 2006;54:763-4.
46. Yajnik CS, Deshpande SS, Lubree HG, et al. Vitamin B12 Deficiency and hyperhomocysteinemia in rural and urban Indians. J Assoc Physicians Ind 2006;54:775-82.
47. Pandey SN, Vaidya ADB, Vaidya RA, et al. Hyperhomocysteinemia as a cardiovascular risk factor in Indian women : Determinants and directionality. J Assoc Physicians Ind 2006;54:769-74.
48. Loomans CJ, de Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction : a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004;53:195-9.
49. Grisar J, Aletaha D, Steiner CW, et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005;111:204-11.
50. Hilgendorff A, Muth H, Parviz B et al. Statins differ in their ability to block NF-kB activation in human blood monocytes. Int J Clin Pharmacol Ther 2003;41:397-401.
51. Abetes AM, Pillinger MH. Statins as anti-inflammatory and immunomodulatory agents. A future in rheumatologic therapy? Arthritis Rheum 2006;54:393-407.
52. Turiel M, Peretti R, Sarzi-Pattini P et al. Cardiac imaging techniques in systemic autoimmune diseases. Lupus 2005;14:727-31.
53. Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004;291:210-5.
54. Chung CP, Oeser A, Raggi P, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2005;52:3045-53.
55. Erbel R, Schmermund A. Clinical significance of coronary calcification (letter). Arterioscler Thromb Vasc Biol 2004;24:e172.